Every 10-Q that ACCUSTEM SCIENCES INC (ACUT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ACUT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ACUT filings page.
AccuStem Sciences Inc. reported another loss-making quarter for the three and six months ended June 30, 2026, as it continues to operate as a clinical-stage diagnostics company with no product revenue. For the quarter, net loss was $252,573, improving from $401,403 a year earlier, while the six‑month net loss was $738,456 versus $841,811 in 2025. Results included $98,400 of other income from supplier credits tied to prior research and development invoices.
Liquidity remains very constrained. As of June 30, 2026, AccuStem had cash of $12,928, total assets of $1.61 million (dominated by a $1.5 million non‑current share-based prepayment for the Gensignia IP transaction), and current liabilities of $5.72 million, resulting in a significant working capital deficit and shareholders’ deficit of $4.12 million. Related party payables totaled several million dollars, and the company states it does not have sufficient cash and current assets to fund operations for 12 months and is actively seeking additional equity financing.
Management continues to prepare statements on a going concern basis but discloses substantial doubt about its ability to continue as a going concern without new funding. The company also reports a material weakness in internal control over financial reporting due to limited accounting resources and inadequate segregation of duties, with plans to recruit additional accounting staff. Development efforts are focused on its MSC lung nodule test and StemPrintER breast cancer assay, with an initial MSC launch targeted for early 2027.
AccuStem Sciences Inc. reported a net loss of $485,883 for the three months ended March 31, 2026, similar to the prior year on a per-share basis at $0.03 loss per share. Research and development spending rose to $119,525, reflecting increased work on its MSC lung nodule test, while general and administrative expenses fell to $366,358.
The balance sheet remains highly leveraged, with total assets of $1.55 million and current liabilities of $5.42 million, resulting in a working capital deficit of $5.37 million and shareholder’s deficit of $3.87 million. Cash was only $12,207, and operations used $374,176 of cash in the quarter, largely funded by $395,000 in advances from a related party.
Management states there is substantial uncertainty about the company’s ability to continue as a going concern and discloses a material weakness in internal control over financial reporting due to limited accounting resources. The company expects existing cash to fund operations only until May 2026 and is actively pursuing additional equity financing.
AccuStem Sciences (ACUT) filed its Q3 2025 10‑Q reporting continued losses and tight liquidity. The company posted a net loss of $399,897 for the quarter and $1,241,708 for the nine months ended September 30, 2025. Cash was $14,391 at quarter‑end against current liabilities of $4,484,157, resulting in a working capital deficit of $2,910,910. Management states there is substantial doubt about the company’s ability to continue as a going concern and it is actively pursuing additional equity financing.
Shares outstanding were 16,072,267 as of November 12, 2025, up from 12,100,535 at December 31, 2024, reflecting an issuance of 3,971,732 shares for $1,579,000 year‑to‑date. Related party payables totaled $3,366,503. Operating expenses rose modestly, with R&D at $72,720 and G&A at $327,177 for the quarter. The company plans to commercialize its MSC lung nodule test and StemPrintER breast cancer assay, noting an 18‑month path of lab transfer and CLIA certification milestones via its partner, EmeritusDx. Management reported a material weakness in internal control over financial reporting and plans to recruit additional accounting resources.